Navigation Links
/C O R R E C T I O N -- Clinical Therapeutics/
Date:9/10/2009

In the news release, "Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section" issued on 9 Sep 2009 08:30 GMT, by Clinical Therapeutics over PR Newswire, we are advised by a representative of the company that the Dateline has been changed from "Bridgewater, England" to "Bridgewater, New Jersey" and the contact number has been changed from +44(0)908-547-2094 to +1-908-547-2094 which were incorrectly transmitted by PR Newswire. Complete, corrected release follows:

, /PRNewswire/ -- Clinical Therapeutics,( http://www.clinicaltherapeutics.com/) the world's premier, rapid-publication journal, is proud to announce the addition of Michael G. Spigarelli, MD, PhD, to our distinguished editorial board.

As section editor for the Pediatric, Adolescent, & Maternal Therapeutics (http://www.clinicaltherapeutics.com/ped.html) section (formerly the Pediatric Research section), Dr. Spigarelli brings a wealth of knowledge and a strong background in addressing the issues surrounding these special populations. He completed his residency in internal medicine and pediatrics at the University of Michigan Medical Center in Ann Arbor and his fellowship in adolescent medicine at Cincinnati Children's Hospital Medical Center, where he currently remains on staff.

Pregnant women and children remain among the most vulnerable patients undergoing therapy today due to a lack of critical information on the safety, tolerability, and efficacy of pharmacotherapies indicated for them. As Dr. Spigarelli states in his inaugural editorial, "To date, most medications used in the treatment of illness in children have never been tested in them.... This lack of crucial information has important implications for a variety of stakeholders."

By refocusing the Pediatric, Adolescent, & Maternal Therapeutics (http://www.clinicaltherapeutics.com/ped.html) section, Clinical Therapeutics(http://www.clinicaltherapeutics.com/) seeks to become the premier venue for publication of clinical research in these special populations and serve as an international forum for the timely discussion of safe and effective drug therapies in neonates, infants, children, adolescents, and pregnant or lactating women.

"As Editor of this section, I encourage each of you to review your files for data already obtained but not yet published, for data from ongoing studies, and consider submitting those manuscripts to Clinical Therapeutics. Each additional piece of available data adds to the knowledge base needed to provide the best health care for pregnant women and children."

An example of important pediatric information published by the journal is the supplemental issue on Conquering Pain: The Hidden Cost of Immunization sponsored by the Canadian Institutes of Health Research and the SickKids Foundation. Also highlighting the journal's commitment to fostering publication of scientific research related to these special populations is the upcoming focus issue on vaccines.

Articles can be submitted online or directly to clinther@elsevier.com; click here for Information for Authors (http://www.clinicaltherapeutics.com/ifa3.html).

For more information about this press release and Clinical Therapeutics, contact Julie E. Artim at:

    Phone: +1-908-547-2094
    Email: ELSRapidPubs@Elsevier.com
    Website: ElsRapidPubs.com


------

Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section

BRIDGEWATER, England, September 9 /PRNewswire/ -- Clinical Therapeutics,( http://www.clinicaltherapeutics.com/) the world's premier, rapid-publication journal, is proud to announce the addition of Michael G. Spigarelli, MD, PhD, to our distinguished editorial board.

As section editor for the Pediatric, Adolescent, & Maternal Therapeutics (http://www.clinicaltherapeutics.com/ped.html) section (formerly the Pediatric Research section), Dr. Spigarelli brings a wealth of knowledge and a strong background in addressing the issues surrounding these special populations. He completed his residency in internal medicine and pediatrics at the University of Michigan Medical Center in Ann Arbor and his fellowship in adolescent medicine at Cincinnati Children's Hospital Medical Center, where he currently remains on staff.

Pregnant women and children remain among the most vulnerable patients undergoing therapy today due to a lack of critical information on the safety, tolerability, and efficacy of pharmacotherapies indicated for them. As Dr. Spigarelli states in his inaugural editorial, "To date, most medications used in the treatment of illness in children have never been tested in them.... This lack of crucial information has important implications for a variety of stakeholders."

By refocusing the Pediatric, Adolescent, & Maternal Therapeutics (http://www.clinicaltherapeutics.com/ped.html) section, Clinical Therapeutics(http://www.clinicaltherapeutics.com/) seeks to become the premier venue for publication of clinical research in these special populations and serve as an international forum for the timely discussion of safe and effective drug therapies in neonates, infants, children, adolescents, and pregnant or lactating women.

"As Editor of this section, I encourage each of you to review your files for data already obtained but not yet published, for data from ongoing studies, and consider submitting those manuscripts to Clinical Therapeutics. Each additional piece of available data adds to the knowledge base needed to provide the best health care for pregnant women and children."

An example of important pediatric information published by the journal is the supplemental issue on Conquering Pain: The Hidden Cost of Immunization sponsored by the Canadian Institutes of Health Research and the SickKids Foundation. Also highlighting the journal's commitment to fostering publication of scientific research related to these special populations is the upcoming focus issue on vaccines.

Articles can be submitted online or directly to clinther@elsevier.com; click here for Information for Authors (http://www.clinicaltherapeutics.com/ifa3.html).

For more information about this press release and Clinical Therapeutics, contact Julie E. Artim at:

    Phone: +44(0)908-547-2094
    Email: ELSRapidPubs@Elsevier.com
    Website: ElsRapidPubs.com



'/>"/>
SOURCE Clinical Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... 3, 2016 New Jersey Health Foundation (NJHF) ... million for researchers in New Jersey ... that demonstrates exciting potential.   James ... the New Jersey Health Foundation Research Grant Program ... educational institutions— Princeton University, Rutgers University, Rowan University ...
(Date:2/3/2016)... ... February 03, 2016 , ... ProMIS Neurosciences is currently in ... to misfolded, propagating strains of Amyloid beta involved in Alzheimer’s disease. The Company ... , Following on from the first misfolded Amyloid beta target announced on Nov. ...
(Date:2/3/2016)... ... February 03, 2016 , ... Resilinc released ... and analyzes nearly 750 unique supply chain notifications and alerts generated by its ... Supply chain risk management practitioners subscribe to the EventWatch service to receive early ...
(Date:2/3/2016)...  Today, Symphony Technology Group (STG) announced the closing ... provider of primary research and analytics-based insight for biopharmaceutical ... a global information and technology services company serving the ... be integrated into IMS Health to form a foundation ... ...
Breaking Biology Technology:
(Date:2/2/2016)...   Parabon NanoLabs (Parabon) announced today ... Office and the Defense Forensics and Biometrics Agency ... company,s Snapshot Kinship Inference software for ... defense-related DNA forensics.  Although Snapshot is best known ... ancestry from DNA evidence), it also has the ...
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of human interface ... 31, 2015. --> --> ... percent compared to the comparable quarter last year to $470.5 million. ... million, or $0.93 per diluted share. --> ... of fiscal 2016 grew 9 percent over the prior year period ...
(Date:1/22/2016)... 2016 http://www.researchandmarkets.com/research/p74whf/global_biometrics ... "Global Biometrics Market in Retail Sector ... --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has announced ... Market in Retail Sector 2016-2020" report ... Research and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has ...
Breaking Biology News(10 mins):